Eli Lilly & Co. Cleared By U.S. Jury In First Cymbalta Withdrawal Lawsuit

Indianapolis-based multinational pharma firm Eli Lilly & Co, has prevailed the first court trial in a series of lawsuits and class actions alleging that the company has failed to provide adequate warning of potential serious side-effects associated with terminating use of its antidepresant drug Cymbalta (duloxetine). Cymbalta is a relatively new antidepressant medication manufactured by Eli Lilly & Co. that was frist was approved by the U.S. Food and Drug Administration to treat major depressive disorder and brought to market in 2004. Belonging to a class of antidepressant drugs known as "serotonin and norepinephrine reuptake inhibitors" (SSRIs/SNRIs) Cymbalta was initially prescribed to treat symptoms associated with major depression, with approval subsequently expanded to include generalized anxiety disorder, fibromyalgia, chronic low back pain, chronic osteoarthritis pain and diabetic nerve pain. Use of Cymbalta as a treatment for fibromyalgia pain in has become popular due to impressive results experienced by many patients. However, lawyers representing plaintiffs in some 250 of lawsuits from people who experienced severe withdrawal symptoms upon cessation of Cymbalta therapy contend that potential side effects associated with use of this drug have been under-advertised and minimized on warning labels by the manufacturer, noting that Cymbalta has been linked to onset of significant and debilitating mental disturbances including mania, suicidal thoughts and insomnia, and that Cymbalta patients additionally are at risk of developing chronic liver problems, seizures, nausea or dizziness. The legal argument is that drugmakers bear responsibility for warning patients of the statistical likelihood of certain conditions or side effects that may result from us
Subscribe or to access all post and page content.